The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Nigels comment.
"Our IP position has strengthened and we believe we are closer than ever before to agreeing a collaboration which would
see Nuvec® being applied to other technologies with a view to co-marketing the resultant technology to big pharma and I
look forward to making further announcements on this in the near future"
Collaborations
· Company continues to seek partners to develop its Nuvec® technology and is in the
advanced stages of finalising a collaboration with an independent global R&D leader based
in the US with the aim of securing a co-marketing agreement following initial studies.
That sounds promising.
I have just asked the following in the telegram group, as I'm wondering the same. I will post the responses when I get one.
"Good to see this has lunched. At what point on the road map dose the project start achieving its end product goal? With it having usage case rather then just another listed cryptocurrency, And do things on the road map have to happen in a set order to get there?"
I belive they just have.
https://twitter.com/pendulum_chain/status/1773004292695150828
Spacewalk live on pendulum.
I'm not going to get drawn into any argument here, the offer is there if anyone wants to take my up on it, I'm not a multi id, life Is far to busy for that. As for names i get far more abuse and names called at work then any one says here so doesn't bother me. Have a good day everyone I expect won't be posting for a while agian.
Hello everyone, I've been invested here for a long time, and see the constant arguments a bickering back on forth and have to say its boring and a bit embarrassing. The most recent is around the new video so I emailed qbt about it and how it's caused confusion and they seem to be damaging. This is a segment of the reply I got(they replied in u der an hr).
"Primarily, these videos were created to spread the word of what QBT is doing to the wider global market – more with possible end-users in mind, rather than shareholders. What we didn’t anticipate is every shareholder would interrogate each and every 30 second clip. So, I don’t think there will be any more now."
So seems they have seen what's going on and are just as unimpressed with it as all the of shareholders that keep quite in the background.
Just listened to the pod cast again, thanks DSFLAT for posting a link for me. I'm not sure if it's his accent or not but I think he says 10s of servers, not 10 servers. So i would sugest that could be anywhere from 10-99.
DSFLAT, I've been here since before it became QBT. I just don't get involved in the constant arguments. I take what fg says at face value and what is published in RNS and PNS as fact. Publishing anything that isn't is unacceptable. So far nothing has been said or done that has made me feel we have been deceived. So I will still belive what is said by him until I feel he has. I work I a roll where I have to take everyone's input as true to them until given reason to doubt it.
I'll now go back to the shadows and watch the interview again.
Thats a valid point. I've had a litle time to read up on the other delivery system, I initially assumed due to the name that it was going to be a liped base delivery wich can have some toxicity issues, so our product may have provided a benefit from that perspective.
However on doing a litle more reading liptide is a artificial virus delivery system, there is some lipeds involved but i belive this is primarly for the relase of the prodcut not the transition into the cell. Like N4p product its very interesting and is able to target specific areas. Liptide seems to do this via protien markers attached to it alwoing it to access/attach to certain cells for delivery.
I would have to go back on my original assumtion, it may be tested to see if it has higher efficancy for delivery but the delivery system seems to do the job.
So two product twice the chance?
The only concerning thing I have come across was the company talking about being in talks with other companys in 2017, but not sure what happened with that or why 6 yesrs later n4p can buy such a big share of the company for the price they got it for.
Sorry for the spelling, I'm on my phone and am very dyslexic.haha.
I might be wrong but I read it all as the company have a product that uses lipids for delivery that is close to being ready for commercialisation.
Then (I make the assumption) N4p by a big chunk of the company to offer the use of their delivery system for the product?
At least that's how I thought this might play out when I read it.